Tampa General Hospital Cancer Institute Secures Reaccreditation Through 2028
Event summary
- Tampa General Hospital Cancer Institute reaccredited by the American College of Surgeons Commission on Cancer until late 2028.
- Institute expanded advanced programs including Cellular Therapy Program, Phase I Cancer Research Unit, and Center for Precision Radiosurgery.
- Received a five-year, $3.1 million NIH grant for research on chronic inflammation and colorectal cancer.
- Sarcoma Center of Excellence accepted into the Sarcoma Alliance for Research through Collaboration.
- Published major study in Annals of Surgical Oncology on Heated Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian cancer.
The big picture
Tampa General Hospital Cancer Institute's reaccreditation underscores its commitment to multidisciplinary care and research-driven innovation. The institute's expansion of advanced programs and successful research initiatives position it as a leader in cancer treatment and academic medicine. The strategic partnership with USF Health Morsani College of Medicine further strengthens its ability to deliver world-class care and drive translational research.
What we're watching
- Research Expansion
- How the $3.1 million NIH grant will accelerate the institute's research on chronic inflammation and colorectal cancer.
- Clinical Innovation
- Whether the new Cellular Therapy Program and Center for Precision Radiosurgery can sustain competitive advantages in cancer treatment.
- Rural Outreach
- The pace at which the institute's outreach to rural communities improves access to early cancer education, screening, and treatment.
Related topics